The Nucleus of Meynert (NBM), also known as the Nucleus Basalis of Meynert, is a prominent group of cholinergic neurons located in the basal forebrain that provides the primary cholinergic innervation to the cerebral cortex 1. These neurons are critical for cognitive function, particularly attention, memory, and arousal, and are prominently affected in Alzheimer's disease (AD) and other neurodegenerative disorders. [1]
The NBM was first described by Theodor Meynert in 1872 as a large collection of neurons in the basal forebrain projecting to the cortex. It has since become a central focus of neurodegenerative research due to its critical role in cholinergic signaling and its degeneration in AD. [2]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000108 | cholinergic neuron |
| Database | ID | Name | Confidence | [3]
|----------|----|------|------------| [4]
| Cell Ontology | CL:0000108 | cholinergic neuron | Medium | [5]
| Cell Ontology | CL:2000056 | Meynert cell | Medium | [6]
The NBM is located in the basal forebrain, specifically:
The NBM can be divided into several subregions:
| Subregion | Abbreviation | Primary Cortical Target |
|---|---|---|
| Ch1 - Septal diagonal band | DB | Hippocampus, olfactory bulb |
| Ch2 - Horizontal limb | HDB | Hippocampus, olfactory tubercle |
| Ch4 - Nucleus basalis | NB | Neocortex, amygdala |
| Ch4p - Posterior part | Ch4p | Parietal, temporal cortex |
The NBM receives input from several brain regions:
| Source | Pathway | Function |
|---|---|---|
| Hippocampus | Septohippocampal loop | Memory feedback |
| Brainstem raphe | Serotonergic input | Modulation |
| Brainstem locus coeruleus | Noradrenergic input | Arousal modulation |
| Hypothalamus | Orexin/hypocretin | Wakefulness |
| Amygdala | Basolateral | Emotional memory |
The NBM projects extensively to the cortex:
| Target Region | Projection Type | Effect |
|---|---|---|
| Frontal Cortex | Dense | Attention, working memory |
| Parietal Cortex | Moderate | Spatial processing |
| Temporal Cortex | Moderate | Memory encoding |
| Occipital Cortex | Sparse | Visual processing |
NBM cholinergic neurons exhibit distinct electrophysiological properties:
The NBM cholinergic system supports several critical cognitive functions:
Acetylcholine released from NBM terminals produces:
| Effect | Mechanism | Cortical Impact |
|---|---|---|
| Desynchronization | Inhibits GABAergic interneurons | Enhanced processing |
| Enhanced plasticity | Activate muscarinic receptors | Learning facilitation |
| Increased blood flow | Vasodilation via NO | Metabolic support |
| Attention enhancement | Reduce background activity | Signal enhancement |
The NBM undergoes severe degeneration in AD:
| Stage | NBM Involvement | Clinical Correlation |
|---|---|---|
| Preclinical | Minimal loss | Asymptomatic |
| MCI | 30-50% loss | Memory complaints |
| Mild AD | 50-70% loss | MMSE 20-26 |
| Moderate AD | 70-85% loss | MMSE 10-19 |
| Severe AD | >90% loss | MMSE <10 |
Several interconnected mechanisms contribute to NBM vulnerability:
The cholinergic hypothesis of AD proposes:
Cholinesterase inhibitors provide symptomatic benefit:
| Drug | Mechanism | Clinical Use |
|---|---|---|
| Donepezil | Reversible AChE inhibitor | First-line AD |
| Rivastigmine | Pseudo-irreversible AChE | Mild-moderate AD |
| Galantamine | Allosteric AChE modulator | Mild-moderate AD |
| Technique | Information Provided |
|---|---|
| ChAT immunohistochemistry | Cholinergic neuron localization |
| Retrograde tracing | Connectivity mapping |
| Electrophysiology | Firing patterns, properties |
| Optogenetics | Circuit function |
| Calcium imaging | Activity patterns in vivo |
Mesulam M. Cholinergic circuitry of the human nucleus basalis. Ann Neurol. 2013. 2013. ↩︎
Hasselmo ME. Neuromodulation and cortical function: modeling the physiological basis of behavior. Behav Brain Res. 1995. 1995. ↩︎
Schliebs R, Arendt T. The significance of the cholinergic system in the development of Alzheimer's disease. Behav Brain Res. 2011. 2011. ↩︎
Baxter MG. Cholinergic cognitive effects of selective basal forebrain lesions in the rat. Behav Neurosci. 2001. 2001. ↩︎
Sarter M, et al. Occupational therapy as symptomatic and disease-modifying therapy for Alzheimer's disease. Nat Rev Neurol. 2009. 2009. ↩︎
Liu L, et al. Nerve growth factor and basal forebrain cholinergic system in Alzheimer's disease. Neurosci Bull. 2014. 2014. ↩︎